Cardiac troponin T following anthracycline chemotherapy in children and adolescents

Journal of Chemotherapy

Volumn 19, Issue 3, 2007, Pages 332-334

  Clark, S J ^a   Pippon, M ^b   Hemsworth, S ^b   Newland, P ^b   Pizer, B ^b  

^a JESSOP HOSPITAL FOR WOMEN   (United Kingdom)

^b ALDER HEY CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

Anthracycline chemotherapy; Cardiac troponin T; Cardiotoxicity; Children

Indexed keywords

ANTHRACYCLINE; DAUNORUBICIN; DOXORUBICIN; TROPONIN T;

ADOLESCENT; ARTICLE; CANCER CHEMOTHERAPY; CHILD; CONTROLLED STUDY; HUMAN; INFANT; LEUKEMIA; OUTCOME ASSESSMENT; PROTEIN SECRETION; SOLID TUMOR;

EID: 34447518514     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2007.19.3.332     Document Type: Article

References (14)

1. Doroshow J. Biochemical mechanisms of anthracylcine cardiac toxicity. In: Muggia FM, Green MD, Speyer JL. (eds) Cancer treatment and the heart 1992. Baltimore: John Hopkins University Press. 1992:124-125.
2. Pihkala J, Sariola H, Saarinen UM. Myocardial function and post mortem myocardial histology in children given anthracycline therapy for cancer. Pediatr Hematol Oncol 1994; 11(3): 259-269.
3. Casper ES, Gaynor JJ, Hajdu SI, et al. A prospective randomised trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high-grade extremity soft tissue sarcoma and an analysis of prognostic factors. Cancer 1991;68(6): 1221-1229.
4. Bhayana V, Henderson AR. Biochemical markers of myocardial damage. Clin Biochem 1995; 28: 1-29.
5. Collinson PO, Stubb PJ. Are troponins confusing? Heart 2003; 89: 1285-1287.
6. Clark SJ, Newland P, Yoxall CW, Subhedar NV. Neonatal levels of cardiac troponin T with and without respiratory distress. Arch Dis Childhood 2004;89: F348-F352.
7. Kismet E, Varan A, Ayabakan C, Alehan D, Portakal O, Buyukpamukcu M. Serum troponin T levels and echocardiographic evaluation in children treated with doxorubicin. Pediatr Blood Cancer 2004;42: 220-224.
8. Lipshultz SE, Rifai N, Sallan SE, et al. Predictive value of cardiac troponin T in paediatric patients at risk for myocardial injury. Circulation 1997;96: 2641-2688.
9. Fink FM, Genser N, Fink C, et al. Cardiac troponin T and creatine kinase MB mass concentration in children receiving anthracycline chemotherapy. Medical Pediatric Oncology 1995;25: 185-189.
10. Anonymous. Troponin T STAT data sheet. Roche Diagnostics GmbH, Mannheim, Germany. January1999.
11. Lipshultz SE, Rifai N, Dalton V, et al. The effect of dexrazone on myocardial injury in doxorubicin treated children with acute lymphoblastic leukaemia. N Engl J Med 2004; 351:145-153.
12. Matthew P, Suarez W, Kip K, et al. Is there a potential role for serum cardiac troponin I as a marker for myocardial dysfunction in paediatric patients receiving anthracylcine based therapy? A pilot study. Cancer Invest 2001;19: 352-359.
13. Auner HW, Tinchon C, Linkesch W, et al. Prolonged monitoring of troponin T for the detection of anthracycline cardiotoxicity in adult with hematological malignancies. Ann Hematol 2003; 82: 218-222.
14. Cardinale D, Sandri MT, Colombo A, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high dose chemotherapy. Circulation 2004;109: 2749-2754.